METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN
To provide methods for treating subjects having a CD20-positive cell proliferative disorder.SOLUTION: The invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.SELECTED DRAWING: Figur...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | IRIS TRANTHUYNGAN TO OKI YASUHIRO CAROL ELAINE O'HEAR |
| description | To provide methods for treating subjects having a CD20-positive cell proliferative disorder.SOLUTION: The invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.SELECTED DRAWING: Figure 2A
【課題】ＣＤ２０陽性細胞増殖性障害を有する対象を処置する方法を提供する。【解決手段】モスネツズマブおよびポラツズマブベドチンの組み合わせを投与する。【選択図】図２Ａ |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2024000507A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2024000507A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2024000507A3</originalsourceid><addsrcrecordid>eNqNjLEKwjAUALs4iPoPD_dCiIpzbF5spO0LyUsFl1I0TqKF-v8oorvTcXDcNLvUyCXpAIY8sEfFttlDoaXIHQXLtkVwnipr0KuPaRvIa_RwtFxCTSE2yPEUa7UD1WhwVKmft6jpPZxnk2t_G9Piy1m2NMhFmafh0aVx6M_pnp7dwUkh10KIjdiq1V_RC_3iNXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN</title><source>esp@cenet</source><creator>IRIS TRANTHUYNGAN TO ; OKI YASUHIRO ; CAROL ELAINE O'HEAR</creator><creatorcontrib>IRIS TRANTHUYNGAN TO ; OKI YASUHIRO ; CAROL ELAINE O'HEAR</creatorcontrib><description>To provide methods for treating subjects having a CD20-positive cell proliferative disorder.SOLUTION: The invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.SELECTED DRAWING: Figure 2A
【課題】ＣＤ２０陽性細胞増殖性障害を有する対象を処置する方法を提供する。【解決手段】モスネツズマブおよびポラツズマブベドチンの組み合わせを投与する。【選択図】図２Ａ</description><language>eng ; jpn</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240105&DB=EPODOC&CC=JP&NR=2024000507A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240105&DB=EPODOC&CC=JP&NR=2024000507A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>IRIS TRANTHUYNGAN TO</creatorcontrib><creatorcontrib>OKI YASUHIRO</creatorcontrib><creatorcontrib>CAROL ELAINE O'HEAR</creatorcontrib><title>METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN</title><description>To provide methods for treating subjects having a CD20-positive cell proliferative disorder.SOLUTION: The invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.SELECTED DRAWING: Figure 2A
【課題】ＣＤ２０陽性細胞増殖性障害を有する対象を処置する方法を提供する。【解決手段】モスネツズマブおよびポラツズマブベドチンの組み合わせを投与する。【選択図】図２Ａ</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEKwjAUALs4iPoPD_dCiIpzbF5spO0LyUsFl1I0TqKF-v8oorvTcXDcNLvUyCXpAIY8sEfFttlDoaXIHQXLtkVwnipr0KuPaRvIa_RwtFxCTSE2yPEUa7UD1WhwVKmft6jpPZxnk2t_G9Piy1m2NMhFmafh0aVx6M_pnp7dwUkh10KIjdiq1V_RC_3iNXw</recordid><startdate>20240105</startdate><enddate>20240105</enddate><creator>IRIS TRANTHUYNGAN TO</creator><creator>OKI YASUHIRO</creator><creator>CAROL ELAINE O'HEAR</creator><scope>EVB</scope></search><sort><creationdate>20240105</creationdate><title>METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN</title><author>IRIS TRANTHUYNGAN TO ; OKI YASUHIRO ; CAROL ELAINE O'HEAR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2024000507A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>IRIS TRANTHUYNGAN TO</creatorcontrib><creatorcontrib>OKI YASUHIRO</creatorcontrib><creatorcontrib>CAROL ELAINE O'HEAR</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>IRIS TRANTHUYNGAN TO</au><au>OKI YASUHIRO</au><au>CAROL ELAINE O'HEAR</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN</title><date>2024-01-05</date><risdate>2024</risdate><abstract>To provide methods for treating subjects having a CD20-positive cell proliferative disorder.SOLUTION: The invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.SELECTED DRAWING: Figure 2A
【課題】ＣＤ２０陽性細胞増殖性障害を有する対象を処置する方法を提供する。【解決手段】モスネツズマブおよびポラツズマブベドチンの組み合わせを投与する。【選択図】図２Ａ</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2024000507A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | METHODS FOR TREATING CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A52%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=IRIS%20TRANTHUYNGAN%20TO&rft.date=2024-01-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2024000507A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |